Elinzanetant Efficacious, Well-Tolerated for Vasomotor Symptoms
By Elana Gotkine HealthDay Reporter
TUESDAY, Aug. 27, 2024 -- For menopausal vasomotor symptoms (VMS), elinzanetant is efficacious and well-tolerated, according to a study published online Aug. 22 in the Journal of the American Medical Association.
JoAnn V. Pinkerton, M.D., from the University of Virginia Health in Charlottesville, and colleagues examined the efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist, for the treatment of moderate-to-severe menopausal VMS in two randomized, double-blind, phase 3 trials (OASIS 1 and 2), including postmenopausal participants aged 40 to 65 years. Eligible participants were randomly assigned to elinzanetant 120 mg for 26 weeks (199 and 200 in OASIS 1 and 2, respectively) or matching placebo for 12 weeks followed by elinzanetant 120 mg for 14 weeks (197 and 200 in OASIS 1 and 2, respectively).
The researchers found a significant reduction in VMS frequency with elinzanetant at week 4 (−3.3 and −3.0 in OASIS 1 and 2, respectively) and week 12 (−3.2 and −3.2 in OASIS 1 and 2, respectively). In addition, the severity of VMS was improved with elinzanetant at week 4 (−0.3 and −0.2 in OASIS 1 and 2, respectively) and week 12 (−0.4 and −0.3 in OASIS 1 and 2, respectively). Improvement in sleep disturbances and menopause-related quality of life was seen with elinzanetant at week 12, and the safety profile was favorable.
"Elinzanetant has the potential to provide a well-tolerated and efficacious nonhormonal treatment option to address the unmet health needs of many menopausal individuals with moderate-to-severe VMS," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Bayer, which manufactures elinzanetant and funded the OASIS 1 and 2 trials.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2024
Read this next
Hormone Therapy Tied to Less Biological Aging in Postmenopausal Women
TUESDAY, Sept. 3, 2024 -- Postmenopausal women who use hormone therapy (HT) are biologically younger than those not receiving HT, according to a study published online Aug. 29...
Menopausal Transition Linked to Adverse Changes in Lipoprotein Profile
FRIDAY, Aug. 30, 2024 -- Menopausal status is associated with adverse changes in lipoprotein profiles, according to a study presented at the European Society of Cardiology...
Severe Menopause Symptoms Tied to Cognitive Impairment
TUESDAY, Aug. 20, 2024 -- Severe menopausal symptoms in postmenopausal women are associated with cognitive impairment, according to a study published online Aug. 13...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.